Agitation is a common sight in psychiatry units, emergency departments, and long-term care facilities, but experts have ambiguous management plans. The United States (US) Food and Drug Administration Center for Drug Evaluation and Research has highlighted that the various definitions of agitation include the presence of “exceeding restlessness associated with mental distress” and “excessive motor activity associated with a feeling of inner tension.” There are many reasons for aggression, and to some degree, it can be a normal physiological process. Traditionally, agitated patients were restrained, secluded, or given high doses of antipsychotics to sedate them; however, over time, less restrictive methods have been used and have shown to be superior while maintaining therapeutic support. Noncoercive methods are most likely to de-escalate situations, but there are times when agitation is so severe that medications must be used voluntarily or involuntarily for safety concerns. Recent recommendations from psychiatry experts are still ambiguous and often confounded by observer’s bias. Aggression can be verbal or physical and directed at objects and other people, and sometimes manifest as self-mutilation. Suicide attempts or gestures are considered a sign of aggression as well. This article reviews different causes of behavioral disturbances, diagnostic cues, and management protocols in different settings.
The etiology of aggression or behavioral disturbance can be multifactorial, reflecting the interaction of precipitating factors and patient characteristics. Agitation, or extreme motor activity or inner restlessness, can be a normal physiological process related to specific situations, but it can also entail an underlying disease. Leading causes of agitation are a new environment, drug intoxication or withdrawal, alcohol in the system, and general medical conditions. Some of the common medical conditions leading to agitation are trauma (especially to the head), generalized infection, sepsis, dementia, delirium, exposure to toxins, electrolyte abnormalities, endocrine abnormalities, and post-ictal state.
Establishing the epidemiology of aggression or behavioral disturbances can be challenging as it differs by age group, general reasons for aggression, confounding interactions, environmental factors, as well as also severity that cannot be objectively and uniformly measured. The most researched places where aggression occurs are long-term care facilities, where professionals can monitor a patient’s day-to-day behavior changes. Hence, these facilities are ideal for research because confounding factors can be minimized. Agitation and aggressive behaviors are reported in 33% of community-dwelling patients with dementia and 80% of institutionalized patients with dementia. Younger age group (16 to 19 years) experienced more aggression than older age group (20 to 26 years). Research indicates a range in prevalence for challenging behaviors, such as self-injury and aggression, of 10% to 20% of all people with intellectual disability. The probability of violent behavior among patients with mental disorders is greater than the probability in the general population. Historically, the consensus was that mental disorders led to aggression and violence. However, modern epidemiological studies have shown that mental disorders have a higher relative risk of aggression and violence, but they are not the sole reason for aggression. A study from Sweden showed that 1 out of 20 patients who have mental disease commit violent crimes including assaults. These findings have been replicated globally in various studies. A Finnish study found that patients with schizophrenia and reported alcohol use were about 25 times more likely (95% CI, 6.1-97.5) to commit violent crimes than mentally healthy patients. Aggression is a global problem that transcends cultures, races, and environments.
Agitation is a nonspecific constellation of relatively unrelated behaviors that can be seen in various clinical situations, usually presenting as a fluctuating course. One of the biggest difficulties in delineating its pathophysiology is its episodic nature, no distinct clinical features, and a non-linear relationship with various neurotransmitters in the body. Multiple neurotransmitters have been postulated to be the cause of aggression. Dysregulations of dopaminergic, serotonergic, noradrenergic, androgens, and GABAergic systems have been most widely studied. Agents that reduce dopaminergic or noradrenergic tone or increase serotonergic or GABAergic tone will attenuate agitation, often irrespective of etiology. Sheard et al hypothesized serotonin 5HT was a modulator of aggression, and later in the same year by Asberg et al. did the same. In inmate populations, Sheard studied effects of lithium for 3 months and concluded that lithium (does have serotonin activity) could have a clinically useful effect on impulsive aggression not related to psychosis. It was Asberg and colleagues who studied cerebrospinal fluid (CSF) of depressed patients and concluded that patients with low level of 5-HIAA, a breakdown product of serotonin, are more likely to commit suicide using more violent means. Further studies verified that low levels of 5-HIAA are significantly associated with more violent attempts. This led to more studies searching for other neurotransmitters involved in aggression.
Experimental studies in which 5-HT activity was manipulated and aggressive responding monitored have been conducted in research volunteers without documented psychopathology. Four studies in which brain 5-HT was putatively manipulated by tryptophan depletion, supplementation, or both reported data consistent with an inverse relationship between 5-HT activity and aggressive response in the laboratory. Based on animal studies, increased noradrenergic (NE) and dopaminergic (DA) activity could be hypothesized to facilitate aggressive response in humans. NE pharmacological challenge studies in this field have been limited and include a positive correlation between the growth hormone response to the alpha 2-NE agonist clonidine and self-reported ‘‘irritability’’ (a type of aggression) in a limited sample of male personality-disordered and healthy volunteer test subjects. Testosterone has also been postulated to play a role in aggression, but aggression levels do not change during puberty when testosterone levels increase.
Furthermore, aggression is not observed more in hypogonadal males when exogenous testosterone is administered, or in hirsute females where androgens levels can double. However, studies like the one by Rasanen et al. have shown that plasma testosterone levels are higher in aggressive individuals in the psychiatric and criminal populations. They also showed that male prisoners with personality disorders had a higher level of plasma testosterone compared to prisoners with schizophrenia. Cortisol, prolactin, and vasopressin have all been postulated to cause aggression, but research shows no conclusive results, Studies have shown that aggression is multifactorial and cannot be attributed to one cause.
During an episode of agitation, obtaining a history is difficult, and in most cases, counterproductive, as patients might retaliate, especially if they are psychotic. Individuals who are agitated do not want to talk about their history, but the initial evaluation is the most important tool that will help a clinician determine the outcome of an episode. After approaching the patient, the clinician should seek to build a rapport and let the patient know they will care that his or her needs and the medical staff are here to help. Once the patients trust the clinician, they may discuss the patient's basic history. Questions should not be leading and assumptions may lead to sudden outbursts. Basic questions should focus on the probable cause of agitation. If the patient has a medical condition that led to the delirium, then focus on orientation questions.
A mental status exam will be necessary. If the patient is agitated due to postictal confusion, then asking about a seizure history is appropriate. If agitation is due to psychosis, it is helpful to talk about the delusions or hallucinations. If the patient is disorganized, then empathy alone can calm the patient. Conduction a physical is appropriate once the patient is redirectable and not agitated. Before doing a physical, always ask them if it is okay for to do a brief exam. If the patient consents, then approach them with care as patients can use stethoscopes, pens, badges, and anything they can get their hands on for assault. Therefore, it is most important to make sure that the patient is calm, not agitated, and not passive-aggressive before approaching them for a physical exam. The physical exam should be focused and brief.
With an agitated patient, the first thing to do is to make sure that the environment is safe. Note anything that can be used as a weapon, for example, chairs, food trays, and other things in the room. Observe any exit points in the examination room and mentally prepare for possible physical attacks. Have staff nearby while talking to an agitated patient as things can escalate rather quickly, especially if the agitated person has a strong built. When engaging, try to keep a safe distance, 1 to 2 arm lengths is ideal. In some instances, physical assaults are unprovoked, and the individual interviewing the patient is not prepared for harmful outcomes. Clinicians should also be careful of their body language and any non-verbal communication. Clinicians should let patients know that they are listening to them and not simply there to dispense medication.
The initial assessment of any agitated patient should be rapid and focused on limiting disruption of the environment as yelling and screaming will make the other patients agitated as well. In some cases, this may lead to physical fights among the other patients. Professionals should then decide whether verbal de-escalation is enough, or if more active treatments like medications, seclusion, or restraints are needed.
Treatment recommendations are outlined by etiology of the agitation, with several alternatives for each category. Individuals involved in the direct care of agitated patients should know the epidemiology and what to expect in the patient population that they will be dealing with, for example, the most common self-harming behaviors and how to manage each of them. The proper management of an agitated patient is essential to keep staff safe and to ensure appropriate treatment for the patient. Treatment teams should be trained in managing any motor unrest and assaultive behaviors and how to tackle these situations with minimal necessary interventions. Such training includes Pro-Act (Professional Assault Crisis Training) that is being implemented globally. In some facilities, annual staff training is mandated to help individuals develop critical thinking in the management of aggressive, behavioral patients. This ultimately reduces the use of unnecessary coercive or sedative treatments that are destructive to the doctor-patient relationship. Training in management of agitated patients also tends to decrease the likelihood of staff and physicians fearing for their safety, and, hence, avoiding proper assessment.
The best way to initially engage agitated patients is through noncoercive de-escalation. De-escalation skills are usually involved in training but can only be improved with practice and real-life application. Clinicians can work on these skills through role-playing and impromptu scenarios. If the patient has a good rapport with a trained healthcare provider, this person should start the initial conversation as the patient already trusts them. The goal is to have the patient believe that their concerns are heard and appropriately addressed. It always helps to repeat what the patient is saying, so they know they are heard. The clinician should ask open-ended questions when trying to de-escalate a volatile situation. If this does not work, one may politely ask the patient if they are willing to take any medications to help them (discussed later). Seclusion is another good method for calming as it there are fewer stimuli, and the patient may calm, but seclusion should never be forced. One should bear in mind that telling a patient to go to the quiet room is different than asking the patient if they would like to be in a quiet room. In specific, severe cases where verbal de-escalation has failed, or patient or staff safety is in question, involuntary medications become necessary. In more severe cases where everything else, including verbal de-escalation, medications, and seclusion has failed, a patient will have to be restrained. Restraints are controversial, specifically because there are cases where unnecessary force led to patient deaths. Fortunately, these rates have decreased in recent years due to preemptive staff training.
During restraint, when staff members physically intervene to subdue a patient, the patient's idea that violence is necessary to resolve the conflict is reinforced. Furthermore, patients who are restrained are more likely to be admitted to a psychiatric hospital and have longer inpatient lengths of stay. The Joint Commission and the Centers for Medicare and Medicaid Services consider low-restraint rates a key quality indicator. Staff and patients are less likely to be hurt when physical confrontation is averted.
When medications must be used, the goal should not be too overly sedate the patient, but to calm them to a point at which they can engage in a conversation. In more severely agitated patients, especially patients actively trying to hurt themselves by biting, hitting their head, or punching walls, sedation may be necessary. If agitation is mild or moderate, medical options should be left to the patient to give them a sense of control and say in the matter. Second-Generation medications are preferred, but consensus can vary among facilities. If, however, the patient is agitated and coming off alcohol then the consensus is to use benzodiazepines instead of antipsychotics. Haloperidol (first-generation antipsychotic) with lorazepam (short-acting benzodiazepine) is an extensively used combination, and there have been numerous studies indicating that haloperidol is as effective as a second-generation antipsychotic either with or without lorazepam. Commonly used second-generation medications like olanzapine, ziprasidone, quetiapine, and risperidone are all equally effective, and it is more a matter of avoiding side effects that lead a physician to choose one medication over another. In all cases, intravenous medications should be used only as a last resort.
Pharmacological Consensus of the Management of Acute Agitation
In all cases, seclusion and restraints are the last resort and should be avoided.
For acute agitation requiring rapid management in the emergency department, American College of Emergency Physicians (ACEP) clinical policy for management recommends the use of benzodiazepines (lorazepam or midazolam) or conventional antipsychotic (droperidol or haloperidol). Addition of benzodiazepines to antipsychotics have not consistently shown improved control of agitation and increases the risk of side effects, including oversedation and respiratory depression. One of the most common medications in the emergency department is butyrophenones (haloperidol and droperidol). Haloperidol and droperidol have been compared with droperidol alone. The result is more rapid control of agitation and/or less need for subsequent dosing. The FDA placed a “black box” warning on droperidol, and later haloperidol, over fears of Torsades des Pointes-inducing QT prolongation. The ACEP Clinical Policy on the management of adult psychiatric patients continues to include droperidol as a recommended treatment option despite the FDA warning as studies have shown conflicting data on droperidol increasing QT interval. Other antipsychotics agents like ziprasidone and olanzapine are marketed as being as effective as the typical antipsychotics with less sedation and fewer extrapyramidal symptoms, but studies have shown that these medications tend to have a slower onset and need more repeated dosing.
For agitation in adult patients with psychiatric conditions, the consensus is to use antipsychotic first or second-generation monotherapy for both management of agitation and initial drug therapy for patients with known mental illness for which antipsychotics are indicated. World Federation of Societies of Biological Psychiatry (WFSBP) recommends that the goal of rapid calming without over-sedating as well as involving patients in the selection of oral or injectable medication to help calm them. Again, this gives patients some sense of control. In mildly agitated patients, oral medications are preferred over intramuscular medications. However, in moderate or severe agitation choosing oral versus injectable medications is a clinical decision. Clinicians should reserve intravenous medications as a last resort. For mild-to-moderate agitation, and when rapid effects of medication are needed, clinicians should consider inhaled formulations of antipsychotics. Furthermore, they should avoid concomitant use of intramuscular olanzapine and benzodiazepines due to possible dangerous effects induced by the interaction of these 2 medications (for example, hypotension, bradycardia, and respiratory depression). Elderly, agitated patients should be treated with lower doses (usually between 25% and 50% of standard adult dose).
For patients with delirium, especially those in the elderly population, haloperidol twice daily has shown the most benefit. Some studies have also demonstrated that using quetiapine twice daily dosing decreases the duration of delirium, however, the efficacy of using second-generation antipsychotic versus first-generation medications remains debatable.
For patients with dementia, the American Psychiatric Association 2016 practice guideline recommends consideration of nonemergency antipsychotic medication only for the management of severe, dangerous, and/or significantly distressing agitation or psychosis. They recommend that reviewing clinical response to nonpharmacologic intervention prior to using any nonemergency antipsychotics for agitation and always assessing the benefit to harm ratio.
In patients whose primary agitation is due to alcohol intoxication or withdrawal, the World Federation of Societies of Biological Psychiatry (WFSBP) recommends benzodiazepines as the preferred over treatment with antipsychotics. American Society of Addiction Medicine (ASAM) recommends that antipsychotics alone can lead to delirium tremens due to increased risk of seizures, and hence, using benzodiazepines is ideal. However, using a combination antipsychotic with benzodiazepines should be considered if agitation, disturbed thinking, or perceptual disturbances not adequately controlled. Benzodiazepines are considered first-line therapy for agitated patients with alcohol withdrawal or central nervous system (CNS) stimulant toxicity, including amphetamines. World Federation of Societies of Biological Psychiatry (WFSBP) also recommends that for agitation associated with alcohol intoxication, antipsychotics be used instead of medicating with benzodiazepines.
In patients with autism spectrum disorder, using risperidone or aripiprazole shows to decrease repetitive and challenging behaviors, like head banging. Risperidone was FDA approved in 2007 after 3 short-term trials showed some benefit in patients with symptoms of aggression toward others, deliberate self-injury, temper tantrums, and quickly changing moods, but only in patients ages 5 to 17 years old. Of note, over 90% of the patients in the trial were younger than 12 years old.
Leading causes of agitation from a general medical condition include trauma as evident during symptoms of headaches, loss of consciousness, acute mental changes, and somnolence.
Delirium is a common cause of agitation and can be attributed to many medical issues most commonly caused by infections or metabolic/electrolyte derangements. Delirium is characterized by waxing and waning cognition leading to spontaneous agitation in confused states. Speech, attention, orientation, and level of consciousness all vary during the episode. Hallucinations, mostly auditory in nature may accompany delirium.
Dementia leads to gradual, or rarely, sudden changes in memory, intellectual abilities, and cognition, leading to increased confusion and agitation. Ongoing medical causes leading to delirium can complicate this. In most cases, the course is progressive, and an accurate history from collaterals can be useful. It is helpful to do a mental status exam on a regular basis, and in some cases where dementia or delirium is severe, doing these mental exams 2 to 3 times a day as a patient's cognition tends to vary throughout the day. Having multiple data sets from mental exams will give clinicians a bigger picture of how the patient is doing.
Psychosis can be from a myriad of related mental or postpartum disorders, certain medications, illicit drugs, sleep deprivation, and medical conditions. Psychosis in psychiatry is seen as a symptom of personality disorders, schizo-spectrum disorders, severe depression, or bipolar disorder. Patients may have delusions, hallucinations, disorganized speech or behavior, and negative symptoms such as anhedonia, apathy, blunt affect, isolation, and impaired attention. It is interesting that patients with acute psychosis are usually fully alert and oriented, but actively psychotic.
Drug intoxication or withdrawal will cause acute severe agitation that is usually short-lived. Patients respond well to treatment in these cases, but drugs like PCP can induce a mania-like state that is difficult to manage. Obtaining a urinary drug screen (UDS) and blood alcohol level is useful in suspected cases if synthetics or designer drugs. A conventional UDS will be negative; therefore, a clinician should obtain an extended UDS which covers most designer drugs.
Agitation is a common feature observed in hospitalized patients. However, the cause of agitation may not always be obvious. Mild agitation can be managed with non-coercive treatments but when it is severe, pharmacological therapy is necessary. The condition is best managed by a multidisciplinary team that includes a neurologist, psychiatrist, internist, primary care provider (nurse practitioner, physician assistant, or physician). The condition can lead to harm to both the patient and the provider, hence, due precautions should be undertaken.
|||Mitolo M,Tonon C,La Morgia C,Testa C,Carelli V,Lodi R, Effects of Light Treatment on Sleep, Cognition, Mood, and Behavior in Alzheimer's Disease: A Systematic Review. Dementia and geriatric cognitive disorders. 2018 Dec 11 [PubMed PMID: 30537760]|
|||Urner M,Ferreyro BL,Douflé G,Mehta S, Supportive Care of Patients on Mechanical Ventilation. Respiratory care. 2018 Dec [PubMed PMID: 30467227]|
|||Mayor S, Person centred care that includes antipsychotic review reduces agitation in dementia patients, finds study. BMJ (Clinical research ed.). 2018 Nov 19 [PubMed PMID: 30459175]|
|||Silić A,Savić A,Čulo I,Kos S,Vukojević J,Brumen D,Ostojić D, Approach to Emergencies in Schizophrenia in University Hospital [PubMed PMID: 29864761]|
|||Siafarikas N,Selbaek G,Fladby T,Šaltytė Benth J,Auning E,Aarsland D, Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer's disease. International psychogeriatrics. 2018 Jan [PubMed PMID: 28927477]|
|||Bauhuis R,Mulders AJMJ,Koopmans RTCM, The course of neuropsychiatric symptoms in institutionalized patients with young onset dementia. Aging [PubMed PMID: 30499335]|
|||Maximous R,Miller F,Tan C,Camargo M,Ross K,Marshall C,Yung P,Fleming D,Law M,Tsang JLY, Pain, agitation and delirium assessment and management in a community medical-surgical ICU: results from a prospective observational study and nurse survey. BMJ open quality. 2018 [PubMed PMID: 30397663]|
|||Devlin JW,Skrobik Y,Gélinas C,Needham DM,Slooter AJC,Pandharipande PP,Watson PL,Weinhouse GL,Nunnally ME,Rochwerg B,Balas MC,van den Boogaard M,Bosma KJ,Brummel NE,Chanques G,Denehy L,Drouot X,Fraser GL,Harris JE,Joffe AM,Kho ME,Kress JP,Lanphere JA,McKinley S,Neufeld KJ,Pisani MA,Payen JF,Pun BT,Puntillo KA,Riker RR,Robinson BRH,Shehabi Y,Szumita PM,Winkelman C,Centofanti JE,Price C,Nikayin S,Misak CJ,Flood PD,Kiedrowski K,Alhazzani W, Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical care medicine. 2018 Sep [PubMed PMID: 30113371]|
|||Souza TL,Azzolin KO,Fernandes VR, Multiprofessional care for delirium patients in intensive care: integrative review. Revista gaucha de enfermagem. 2018 Aug 2 [PubMed PMID: 30088606]|
|||Anderson KE,van Duijn E,Craufurd D,Drazinic C,Edmondson M,Goodman N,van Kammen D,Loy C,Priller J,Goodman LV, Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders. Journal of Huntington's disease. 2018 [PubMed PMID: 30040737]|
|||Lofchy J, Agitation and CANMAT and ISBD 2018 Bipolar Guidelines. Bipolar disorders. 2018 Jul 18 [PubMed PMID: 30022579]|
|||Spencer S,Johnson P,Smith IC, De-escalation techniques for managing non-psychosis induced aggression in adults. The Cochrane database of systematic reviews. 2018 Jul 18 [PubMed PMID: 30019748]|
|||Tsuruta R,Fujita M, Comparison of clinical practice guidelines for the management of pain, agitation, and delirium in critically ill adult patients. Acute medicine [PubMed PMID: 29988658]|